Serologicals homes in on SARS (severe acute respiratory syndrome):
This article was originally published in Clinica
Executive Summary
Serologicals' research division Chemicon International is to launch a qualitative nucleic acid test for detecting SARS (severe acute respiratory syndrome) in its early phase. The OligoDetect assay consists of a simple ELISA-based colorimetric procedure and a microplate reader. It can be used easily by laboratories that do not have costly real-time instrumentation to run assays, says the firm. Capable of producing a result in under three hours, the test will be available as an FDA listed analyte-specific reagent from Chemicon and its worldwide distributor network. Atlanta, Georgia based Serologicals recently announced plans to discontinue its therapeutic plasma business and to focus on its segments for cell culture supplements, research reagents and diagnostic antibodies.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.